Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ORGANIZATION
ORGANIZATION
- Hodanren Opposes Generic Use Requirement for Welfare Recipients
February 23, 2018
- JPMA to Compile Counterproposal for New PMP Scheme ASAP
February 16, 2018
- Astellas Becomes 1st Japan Maker to Join PhRMA Leadership
February 14, 2018
- Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules
February 9, 2018
- “Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura
February 8, 2018
- Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
January 30, 2018
- Japan Pharma Leader Says Pricing Overhaul Would Not Expand Drug Lag
January 18, 2018
- Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief
January 15, 2018
- Pharma Leaders Air Bleak Outlook on New PMP Scheme at New Year’s Reception
January 10, 2018
- JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
- Continued Discussions Needed for PMP-Eligible Products, Company Criteria: FPMAJ/JPMA
December 22, 2017
- PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences
December 21, 2017
- Novo Pres. Bech Re-Elected as EFPIA Japan Chief
December 18, 2017
- GHIT Fund’s New 5-Year Strategic Plan Aims to Win Approval of 2 Products
December 12, 2017
- PhRMA/EFPIA to Govt: Make Major Changes to Drug Pricing Proposal, It Will Tarnish Japan’s Reputation
December 11, 2017
- PhRMA Stands Pat on PMP Push, Says Minor Modification to Govt Proposal “Far from Sufficient”
December 8, 2017
- PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
- Hodanren Petitions Health and Finance Ministers to “Abolish the Price Maintenance Premium”
November 22, 2017
- Patrik Jonsson to Remain PhRMA Japan Chief as Pricing Reform Debate Continues
November 20, 2017
- Deeper Price Cuts Needed for Off-Patent Brands, Scrap 5-Year Grace Period: Chuikyo Payer Rep
November 14, 2017
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…